#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Diy_coref|
#T_RL=webanno.custom.Diy_coref_re|BT_webanno.custom.Diy_coref


#Text=[0119] The steps of a representative protocol for profiling gene expression using fixed, paraffin-embedded tissues as the RNA source, including mRNA isolation, purification, primer extension and amplification are given in various published journal articles {for example: T.
1-1	0-1	[	_	_	
1-2	1-5	0119	_	_	
1-3	5-6	]	_	_	
1-4	7-10	The	_	_	
1-5	11-16	steps	_	_	
1-6	17-19	of	_	_	
1-7	20-21	a	_	_	
1-8	22-36	representative	_	_	
1-9	37-45	protocol	_	_	
1-10	46-49	for	_	_	
1-11	50-59	profiling	_	_	
1-12	60-64	gene	_	_	
1-13	65-75	expression	_	_	
1-14	76-81	using	_	_	
1-15	82-87	fixed	_	_	
1-16	87-88	,	_	_	
1-17	89-106	paraffin-embedded	_	_	
1-18	107-114	tissues	_	_	
1-19	115-117	as	_	_	
1-20	118-121	the	_	_	
1-21	122-125	RNA	_	_	
1-22	126-132	source	_	_	
1-23	132-133	,	_	_	
1-24	134-143	including	_	_	
1-25	144-148	mRNA	_	_	
1-26	149-158	isolation	_	_	
1-27	158-159	,	_	_	
1-28	160-172	purification	_	_	
1-29	172-173	,	_	_	
1-30	174-180	primer	_	_	
1-31	181-190	extension	_	_	
1-32	191-194	and	_	_	
1-33	195-208	amplification	_	_	
1-34	209-212	are	_	_	
1-35	213-218	given	_	_	
1-36	219-221	in	_	_	
1-37	222-229	various	_	_	
1-38	230-239	published	_	_	
1-39	240-247	journal	_	_	
1-40	248-256	articles	_	_	
1-41	257-258	{	_	_	
1-42	258-261	for	_	_	
1-43	262-269	example	_	_	
1-44	269-270	:	_	_	
1-45	271-272	T	_	_	
1-46	272-273	.	_	_	

#Text=E.
2-1	274-275	E	_	_	
2-2	275-276	.	_	_	

#Text=Godfrey et al.
3-1	277-284	Godfrey	_	_	
3-2	285-287	et	_	_	
3-3	288-290	al	_	_	
3-4	290-291	.	_	_	

#Text=J.
4-1	292-293	J	_	_	
4-2	293-294	.	_	_	

#Text=Molec.
5-1	295-300	Molec	_	_	
5-2	300-301	.	_	_	

#Text=Diagnostics 2: 84-91 (2000); K.
6-1	302-313	Diagnostics	_	_	
6-2	314-315	2	_	_	
6-3	315-316	:	_	_	
6-4	317-319	84	_	_	
6-5	319-320	-	_	_	
6-6	320-322	91	_	_	
6-7	323-324	(	_	_	
6-8	324-328	2000	_	_	
6-9	328-329	)	_	_	
6-10	329-330	;	_	_	
6-11	331-332	K	_	_	
6-12	332-333	.	_	_	

#Text=Specht et al., Am.
7-1	334-340	Specht	_	_	
7-2	341-343	et	_	_	
7-3	344-346	al	_	_	
7-4	346-347	.	_	_	
7-5	347-348	,	_	_	
7-6	349-351	Am	_	_	
7-7	351-352	.	_	_	

#Text=J.
8-1	353-354	J	_	_	
8-2	354-355	.	_	_	

#Text=Pathol. 158: 419-29 (2001); Cronin et al., Am J Pathol 164:35-42 (2004)}.
9-1	356-362	Pathol	_	_	
9-2	362-363	.	_	_	
9-3	364-367	158	_	_	
9-4	367-368	:	_	_	
9-5	369-372	419	_	_	
9-6	372-373	-	_	_	
9-7	373-375	29	_	_	
9-8	376-377	(	_	_	
9-9	377-381	2001	_	_	
9-10	381-382	)	_	_	
9-11	382-383	;	_	_	
9-12	384-390	Cronin	_	_	
9-13	391-393	et	_	_	
9-14	394-396	al	_	_	
9-15	396-397	.	_	_	
9-16	397-398	,	_	_	
9-17	399-401	Am	_	_	
9-18	402-403	J	_	_	
9-19	404-410	Pathol	_	_	
9-20	411-414	164	_	_	
9-21	414-415	:	_	_	
9-22	415-417	35	_	_	
9-23	417-418	-	_	_	
9-24	418-420	42	_	_	
9-25	421-422	(	_	_	
9-26	422-426	2004	_	_	
9-27	426-427	)	_	_	
9-28	427-428	}	_	_	
9-29	428-429	.	_	_	

#Text=Briefly, a representative process starts with cutting about 10 .mu.m thick sections of paraffin-embedded tumor tissue samples.
10-1	430-437	Briefly	_	_	
10-2	437-438	,	_	_	
10-3	439-440	a	_	_	
10-4	441-455	representative	_	_	
10-5	456-463	process	_	_	
10-6	464-470	starts	_	_	
10-7	471-475	with	_	_	
10-8	476-483	cutting	_	_	
10-9	484-489	about	_	_	
10-10	490-492	10	_	_	
10-11	493-494	.	_	_	
10-12	494-498	mu.m	_	_	
10-13	499-504	thick	_	_	
10-14	505-513	sections	_	_	
10-15	514-516	of	_	_	
10-16	517-534	paraffin-embedded	_	_	
10-17	535-540	tumor	_	_	
10-18	541-547	tissue	_	_	
10-19	548-555	samples	_	_	
10-20	555-556	.	_	_	

#Text=The RNA is then extracted, and protein and DNA are removed.
11-1	557-560	The	_	_	
11-2	561-564	RNA	_	_	
11-3	565-567	is	_	_	
11-4	568-572	then	_	_	
11-5	573-582	extracted	_	_	
11-6	582-583	,	_	_	
11-7	584-587	and	_	_	
11-8	588-595	protein	_	_	
11-9	596-599	and	_	_	
11-10	600-603	DNA	_	_	
11-11	604-607	are	_	_	
11-12	608-615	removed	_	_	
11-13	615-616	.	_	_	

#Text=After analysis of the RNA concentration, RNA repair and/or amplification steps may be included, if necessary, and RNA is reverse transcribed using gene specific promoters followed by RT-PCR.
#Text=[0120] b.
12-1	617-622	After	_	_	
12-2	623-631	analysis	_	_	
12-3	632-634	of	_	_	
12-4	635-638	the	_	_	
12-5	639-642	RNA	_	_	
12-6	643-656	concentration	_	_	
12-7	656-657	,	_	_	
12-8	658-661	RNA	_	_	
12-9	662-668	repair	_	_	
12-10	669-672	and	_	_	
12-11	672-673	/	_	_	
12-12	673-675	or	_	_	
12-13	676-689	amplification	_	_	
12-14	690-695	steps	_	_	
12-15	696-699	may	_	_	
12-16	700-702	be	_	_	
12-17	703-711	included	_	_	
12-18	711-712	,	_	_	
12-19	713-715	if	_	_	
12-20	716-725	necessary	_	_	
12-21	725-726	,	_	_	
12-22	727-730	and	_	_	
12-23	731-734	RNA	_	_	
12-24	735-737	is	_	_	
12-25	738-745	reverse	_	_	
12-26	746-757	transcribed	_	_	
12-27	758-763	using	_	_	
12-28	764-768	gene	_	_	
12-29	769-777	specific	_	_	
12-30	778-787	promoters	_	_	
12-31	788-796	followed	_	_	
12-32	797-799	by	_	_	
12-33	800-806	RT-PCR	_	_	
12-34	806-807	.	_	_	
12-35	808-809	[	_	_	
12-36	809-813	0120	_	_	
12-37	813-814	]	_	_	
12-38	815-816	b	_	_	
12-39	816-817	.	_	_	

#Text=Microarrays
#Text=[0121] Differential gene expression can also be identified, or confirmed using the microarray technique.
13-1	818-829	Microarrays	_	_	
13-2	830-831	[	*[1]	15-2[2_1]	
13-3	831-835	0121	*[1]	_	
13-4	835-836	]	*[1]	_	
13-5	837-849	Differential	*[1]	_	
13-6	850-854	gene	*[1]	_	
13-7	855-865	expression	*[1]	_	
13-8	866-869	can	*[1]	_	
13-9	870-874	also	*[1]	_	
13-10	875-877	be	*[1]	_	
13-11	878-888	identified	*[1]	_	
13-12	888-889	,	*[1]	_	
13-13	890-892	or	*[1]	_	
13-14	893-902	confirmed	*[1]	_	
13-15	903-908	using	*[1]	_	
13-16	909-912	the	*[1]	_	
13-17	913-923	microarray	*[1]	_	
13-18	924-933	technique	*[1]	_	
13-19	933-934	.	*[1]	_	

#Text=Thus, the expression profile of breast cancer-associated genes can be measured in either fresh or paraffin-embedded tumor tissue, using microarray technology.
14-1	935-939	Thus	_	_	
14-2	939-940	,	_	_	
14-3	941-944	the	_	_	
14-4	945-955	expression	_	_	
14-5	956-963	profile	_	_	
14-6	964-966	of	_	_	
14-7	967-973	breast	_	_	
14-8	974-991	cancer-associated	_	_	
14-9	992-997	genes	_	_	
14-10	998-1001	can	_	_	
14-11	1002-1004	be	_	_	
14-12	1005-1013	measured	_	_	
14-13	1014-1016	in	_	_	
14-14	1017-1023	either	_	_	
14-15	1024-1029	fresh	_	_	
14-16	1030-1032	or	_	_	
14-17	1033-1050	paraffin-embedded	_	_	
14-18	1051-1056	tumor	_	_	
14-19	1057-1063	tissue	_	_	
14-20	1063-1064	,	_	_	
14-21	1065-1070	using	_	_	
14-22	1071-1081	microarray	_	_	
14-23	1082-1092	technology	_	_	
14-24	1092-1093	.	_	_	

#Text=In this method, polynucleotide sequences of interest (including cDNAs and oligonucleotides) are plated, or arrayed, on a microchip substrate.
15-1	1094-1096	In	_	_	
15-2	1097-1101	this	*[2]	_	
15-3	1102-1108	method	*[2]	_	
15-4	1108-1109	,	_	_	
15-5	1110-1124	polynucleotide	_	_	
15-6	1125-1134	sequences	_	_	
15-7	1135-1137	of	_	_	
15-8	1138-1146	interest	_	_	
15-9	1147-1148	(	_	_	
15-10	1148-1157	including	_	_	
15-11	1158-1163	cDNAs	_	_	
15-12	1164-1167	and	_	_	
15-13	1168-1184	oligonucleotides	_	_	
15-14	1184-1185	)	_	_	
15-15	1186-1189	are	_	_	
15-16	1190-1196	plated	_	_	
15-17	1196-1197	,	_	_	
15-18	1198-1200	or	_	_	
15-19	1201-1208	arrayed	_	_	
15-20	1208-1209	,	_	_	
15-21	1210-1212	on	_	_	
15-22	1213-1214	a	_	_	
15-23	1215-1224	microchip	_	_	
15-24	1225-1234	substrate	_	_	
15-25	1234-1235	.	_	_	

#Text=The arrayed sequences are then hybridized with specific DNA probes from cells or tissues of interest.
16-1	1236-1239	The	_	_	
16-2	1240-1247	arrayed	_	_	
16-3	1248-1257	sequences	_	_	
16-4	1258-1261	are	_	_	
16-5	1262-1266	then	_	_	
16-6	1267-1277	hybridized	_	_	
16-7	1278-1282	with	_	_	
16-8	1283-1291	specific	_	_	
16-9	1292-1295	DNA	_	_	
16-10	1296-1302	probes	_	_	
16-11	1303-1307	from	_	_	
16-12	1308-1313	cells	_	_	
16-13	1314-1316	or	_	_	
16-14	1317-1324	tissues	_	_	
16-15	1325-1327	of	_	_	
16-16	1328-1336	interest	_	_	
16-17	1336-1337	.	_	_	

#Text=Just as in the RT-PCR method, the source of mRNA typically is total RNA isolated from human tumors or tumor cell lines, and corresponding normal tissues or cell lines.
17-1	1338-1342	Just	_	_	
17-2	1343-1345	as	_	_	
17-3	1346-1348	in	_	_	
17-4	1349-1352	the	_	_	
17-5	1353-1359	RT-PCR	_	_	
17-6	1360-1366	method	_	_	
17-7	1366-1367	,	_	_	
17-8	1368-1371	the	_	_	
17-9	1372-1378	source	_	_	
17-10	1379-1381	of	_	_	
17-11	1382-1386	mRNA	_	_	
17-12	1387-1396	typically	_	_	
17-13	1397-1399	is	_	_	
17-14	1400-1405	total	_	_	
17-15	1406-1409	RNA	_	_	
17-16	1410-1418	isolated	_	_	
17-17	1419-1423	from	_	_	
17-18	1424-1429	human	_	_	
17-19	1430-1436	tumors	_	_	
17-20	1437-1439	or	_	_	
17-21	1440-1445	tumor	_	_	
17-22	1446-1450	cell	_	_	
17-23	1451-1456	lines	_	_	
17-24	1456-1457	,	_	_	
17-25	1458-1461	and	_	_	
17-26	1462-1475	corresponding	_	_	
17-27	1476-1482	normal	_	_	
17-28	1483-1490	tissues	_	_	
17-29	1491-1493	or	_	_	
17-30	1494-1498	cell	_	_	
17-31	1499-1504	lines	_	_	
17-32	1504-1505	.	_	_	

#Text=Thus RNA can be isolated from a variety of primary tumors or tumor cell lines.
18-1	1506-1510	Thus	_	_	
18-2	1511-1514	RNA	_	_	
18-3	1515-1518	can	_	_	
18-4	1519-1521	be	_	_	
18-5	1522-1530	isolated	_	_	
18-6	1531-1535	from	_	_	
18-7	1536-1537	a	_	_	
18-8	1538-1545	variety	_	_	
18-9	1546-1548	of	_	_	
18-10	1549-1556	primary	_	_	
18-11	1557-1563	tumors	_	_	
18-12	1564-1566	or	_	_	
18-13	1567-1572	tumor	_	_	
18-14	1573-1577	cell	_	_	
18-15	1578-1583	lines	_	_	
18-16	1583-1584	.	_	_	

#Text=If the source of mRNA is a primary tumor, mRNA can be extracted, for example, from frozen or archived paraffin-embedded and fixed (e.g. formalin-fixed) tissue samples, which are routinely prepared and preserved in everyday clinical practice.
#Text=[0122] In a specific embodiment of the microarray technique, PCR amplified inserts of cDNA clones are applied to a substrate in a dense array.
19-1	1585-1587	If	_	_	
19-2	1588-1591	the	_	_	
19-3	1592-1598	source	_	_	
19-4	1599-1601	of	_	_	
19-5	1602-1606	mRNA	_	_	
19-6	1607-1609	is	_	_	
19-7	1610-1611	a	_	_	
19-8	1612-1619	primary	_	_	
19-9	1620-1625	tumor	_	_	
19-10	1625-1626	,	_	_	
19-11	1627-1631	mRNA	_	_	
19-12	1632-1635	can	_	_	
19-13	1636-1638	be	_	_	
19-14	1639-1648	extracted	_	_	
19-15	1648-1649	,	_	_	
19-16	1650-1653	for	_	_	
19-17	1654-1661	example	_	_	
19-18	1661-1662	,	_	_	
19-19	1663-1667	from	_	_	
19-20	1668-1674	frozen	_	_	
19-21	1675-1677	or	_	_	
19-22	1678-1686	archived	_	_	
19-23	1687-1704	paraffin-embedded	_	_	
19-24	1705-1708	and	_	_	
19-25	1709-1714	fixed	_	_	
19-26	1715-1716	(	_	_	
19-27	1716-1719	e.g	_	_	
19-28	1719-1720	.	_	_	
19-29	1721-1735	formalin-fixed	_	_	
19-30	1735-1736	)	_	_	
19-31	1737-1743	tissue	_	_	
19-32	1744-1751	samples	_	_	
19-33	1751-1752	,	_	_	
19-34	1753-1758	which	_	_	
19-35	1759-1762	are	_	_	
19-36	1763-1772	routinely	_	_	
19-37	1773-1781	prepared	_	_	
19-38	1782-1785	and	_	_	
19-39	1786-1795	preserved	_	_	
19-40	1796-1798	in	_	_	
19-41	1799-1807	everyday	_	_	
19-42	1808-1816	clinical	_	_	
19-43	1817-1825	practice	_	_	
19-44	1825-1826	.	_	_	
19-45	1827-1828	[	_	_	
19-46	1828-1832	0122	_	_	
19-47	1832-1833	]	_	_	
19-48	1834-1836	In	_	_	
19-49	1837-1838	a	_	_	
19-50	1839-1847	specific	_	_	
19-51	1848-1858	embodiment	_	_	
19-52	1859-1861	of	_	_	
19-53	1862-1865	the	_	_	
19-54	1866-1876	microarray	_	_	
19-55	1877-1886	technique	_	_	
19-56	1886-1887	,	_	_	
19-57	1888-1891	PCR	_	_	
19-58	1892-1901	amplified	_	_	
19-59	1902-1909	inserts	_	_	
19-60	1910-1912	of	_	_	
19-61	1913-1917	cDNA	_	_	
19-62	1918-1924	clones	_	_	
19-63	1925-1928	are	_	_	
19-64	1929-1936	applied	_	_	
19-65	1937-1939	to	_	_	
19-66	1940-1941	a	_	_	
19-67	1942-1951	substrate	_	_	
19-68	1952-1954	in	_	_	
19-69	1955-1956	a	_	_	
19-70	1957-1962	dense	_	_	
19-71	1963-1968	array	_	_	
19-72	1968-1969	.	_	_	

#Text=Preferably at least 10,000 nucleotide sequences are applied to the substrate.
20-1	1970-1980	Preferably	_	_	
20-2	1981-1983	at	_	_	
20-3	1984-1989	least	_	_	
20-4	1990-1996	10,000	_	_	
20-5	1997-2007	nucleotide	_	_	
20-6	2008-2017	sequences	_	_	
20-7	2018-2021	are	_	_	
20-8	2022-2029	applied	_	_	
20-9	2030-2032	to	_	_	
20-10	2033-2036	the	_	_	
20-11	2037-2046	substrate	_	_	
20-12	2046-2047	.	_	_	

#Text=The microarrayed genes, immobilized on the microchip at 10,000 elements each, are suitable for hybridization under stringent conditions.
21-1	2048-2051	The	_	_	
21-2	2052-2064	microarrayed	_	_	
21-3	2065-2070	genes	_	_	
21-4	2070-2071	,	_	_	
21-5	2072-2083	immobilized	_	_	
21-6	2084-2086	on	_	_	
21-7	2087-2090	the	_	_	
21-8	2091-2100	microchip	_	_	
21-9	2101-2103	at	_	_	
21-10	2104-2110	10,000	_	_	
21-11	2111-2119	elements	_	_	
21-12	2120-2124	each	_	_	
21-13	2124-2125	,	_	_	
21-14	2126-2129	are	_	_	
21-15	2130-2138	suitable	_	_	
21-16	2139-2142	for	_	_	
21-17	2143-2156	hybridization	_	_	
21-18	2157-2162	under	_	_	
21-19	2163-2172	stringent	_	_	
21-20	2173-2183	conditions	_	_	
21-21	2183-2184	.	_	_	

#Text=Fluorescently labeled cDNA probes may be generated through incorporation of fluorescent nucleotides by reverse transcription of RNA extracted from tissues of interest.
22-1	2185-2198	Fluorescently	_	_	
22-2	2199-2206	labeled	_	_	
22-3	2207-2211	cDNA	_	_	
22-4	2212-2218	probes	_	_	
22-5	2219-2222	may	_	_	
22-6	2223-2225	be	_	_	
22-7	2226-2235	generated	_	_	
22-8	2236-2243	through	_	_	
22-9	2244-2257	incorporation	_	_	
22-10	2258-2260	of	_	_	
22-11	2261-2272	fluorescent	_	_	
22-12	2273-2284	nucleotides	_	_	
22-13	2285-2287	by	_	_	
22-14	2288-2295	reverse	_	_	
22-15	2296-2309	transcription	_	_	
22-16	2310-2312	of	_	_	
22-17	2313-2316	RNA	_	_	
22-18	2317-2326	extracted	_	_	
22-19	2327-2331	from	_	_	
22-20	2332-2339	tissues	_	_	
22-21	2340-2342	of	_	_	
22-22	2343-2351	interest	_	_	
22-23	2351-2352	.	_	_	

#Text=Labeled cDNA probes applied to the chip hybridize with specificity to each spot of DNA on the array.
23-1	2353-2360	Labeled	_	_	
23-2	2361-2365	cDNA	_	_	
23-3	2366-2372	probes	_	_	
23-4	2373-2380	applied	_	_	
23-5	2381-2383	to	_	_	
23-6	2384-2387	the	_	_	
23-7	2388-2392	chip	_	_	
23-8	2393-2402	hybridize	_	_	
23-9	2403-2407	with	_	_	
23-10	2408-2419	specificity	_	_	
23-11	2420-2422	to	_	_	
23-12	2423-2427	each	_	_	
23-13	2428-2432	spot	_	_	
23-14	2433-2435	of	_	_	
23-15	2436-2439	DNA	_	_	
23-16	2440-2442	on	_	_	
23-17	2443-2446	the	_	_	
23-18	2447-2452	array	_	_	
23-19	2452-2453	.	_	_	

#Text=After stringent washing to remove non-specifically bound probes, the chip is scanned by confocal laser microscopy or by another detection method, such as a CCD camera.
24-1	2454-2459	After	_	_	
24-2	2460-2469	stringent	_	_	
24-3	2470-2477	washing	_	_	
24-4	2478-2480	to	_	_	
24-5	2481-2487	remove	_	_	
24-6	2488-2504	non-specifically	_	_	
24-7	2505-2510	bound	_	_	
24-8	2511-2517	probes	_	_	
24-9	2517-2518	,	_	_	
24-10	2519-2522	the	_	_	
24-11	2523-2527	chip	_	_	
24-12	2528-2530	is	_	_	
24-13	2531-2538	scanned	_	_	
24-14	2539-2541	by	_	_	
24-15	2542-2550	confocal	_	_	
24-16	2551-2556	laser	_	_	
24-17	2557-2567	microscopy	_	_	
24-18	2568-2570	or	_	_	
24-19	2571-2573	by	_	_	
24-20	2574-2581	another	_	_	
24-21	2582-2591	detection	_	_	
24-22	2592-2598	method	_	_	
24-23	2598-2599	,	_	_	
24-24	2600-2604	such	_	_	
24-25	2605-2607	as	_	_	
24-26	2608-2609	a	_	_	
24-27	2610-2613	CCD	_	_	
24-28	2614-2620	camera	_	_	
24-29	2620-2621	.	_	_	

#Text=Quantitation of hybridization of each arrayed element allows for assessment of corresponding mRNA abundance.
25-1	2622-2634	Quantitation	_	_	
25-2	2635-2637	of	_	_	
25-3	2638-2651	hybridization	_	_	
25-4	2652-2654	of	_	_	
25-5	2655-2659	each	_	_	
25-6	2660-2667	arrayed	_	_	
25-7	2668-2675	element	_	_	
25-8	2676-2682	allows	_	_	
25-9	2683-2686	for	_	_	
25-10	2687-2697	assessment	_	_	
25-11	2698-2700	of	_	_	
25-12	2701-2714	corresponding	_	_	
25-13	2715-2719	mRNA	_	_	
25-14	2720-2729	abundance	_	_	
25-15	2729-2730	.	_	_	

#Text=With dual color fluorescence, separately labeled cDNA probes generated from two sources of RNA are hybridized pairwise to the array.
26-1	2731-2735	With	_	_	
26-2	2736-2740	dual	_	_	
26-3	2741-2746	color	_	_	
26-4	2747-2759	fluorescence	_	_	
26-5	2759-2760	,	_	_	
26-6	2761-2771	separately	_	_	
26-7	2772-2779	labeled	_	_	
26-8	2780-2784	cDNA	_	_	
26-9	2785-2791	probes	_	_	
26-10	2792-2801	generated	_	_	
26-11	2802-2806	from	_	_	
26-12	2807-2810	two	_	_	
26-13	2811-2818	sources	_	_	
26-14	2819-2821	of	_	_	
26-15	2822-2825	RNA	_	_	
26-16	2826-2829	are	_	_	
26-17	2830-2840	hybridized	_	_	
26-18	2841-2849	pairwise	_	_	
26-19	2850-2852	to	_	_	
26-20	2853-2856	the	_	_	
26-21	2857-2862	array	_	_	
26-22	2862-2863	.	_	_	

#Text=The relative abundance of the transcripts from the two sources corresponding to each specified gene is thus determined simultaneously.
27-1	2864-2867	The	_	_	
27-2	2868-2876	relative	_	_	
27-3	2877-2886	abundance	_	_	
27-4	2887-2889	of	_	_	
27-5	2890-2893	the	_	_	
27-6	2894-2905	transcripts	_	_	
27-7	2906-2910	from	_	_	
27-8	2911-2914	the	_	_	
27-9	2915-2918	two	_	_	
27-10	2919-2926	sources	_	_	
27-11	2927-2940	corresponding	_	_	
27-12	2941-2943	to	_	_	
27-13	2944-2948	each	_	_	
27-14	2949-2958	specified	_	_	
27-15	2959-2963	gene	_	_	
27-16	2964-2966	is	_	_	
27-17	2967-2971	thus	_	_	
27-18	2972-2982	determined	_	_	
27-19	2983-2997	simultaneously	_	_	
27-20	2997-2998	.	_	_	

#Text=The miniaturized scale of the hybridization affords a convenient and rapid evaluation of the expression pattern for large numbers of genes.
28-1	2999-3002	The	_	_	
28-2	3003-3015	miniaturized	_	_	
28-3	3016-3021	scale	_	_	
28-4	3022-3024	of	_	_	
28-5	3025-3028	the	_	_	
28-6	3029-3042	hybridization	_	_	
28-7	3043-3050	affords	_	_	
28-8	3051-3052	a	_	_	
28-9	3053-3063	convenient	_	_	
28-10	3064-3067	and	_	_	
28-11	3068-3073	rapid	_	_	
28-12	3074-3084	evaluation	_	_	
28-13	3085-3087	of	_	_	
28-14	3088-3091	the	_	_	
28-15	3092-3102	expression	_	_	
28-16	3103-3110	pattern	_	_	
28-17	3111-3114	for	_	_	
28-18	3115-3120	large	_	_	
28-19	3121-3128	numbers	_	_	
28-20	3129-3131	of	_	_	
28-21	3132-3137	genes	_	_	
28-22	3137-3138	.	_	_	

#Text=Such methods have been shown to have the sensitivity required to detect rare transcripts, which are expressed at a few copies per cell, and to reproducibly detect at least approximately two-fold differences in the expression levels (Schena et al., Proc.
29-1	3139-3143	Such	_	_	
29-2	3144-3151	methods	_	_	
29-3	3152-3156	have	_	_	
29-4	3157-3161	been	_	_	
29-5	3162-3167	shown	_	_	
29-6	3168-3170	to	_	_	
29-7	3171-3175	have	_	_	
29-8	3176-3179	the	_	_	
29-9	3180-3191	sensitivity	_	_	
29-10	3192-3200	required	_	_	
29-11	3201-3203	to	_	_	
29-12	3204-3210	detect	_	_	
29-13	3211-3215	rare	_	_	
29-14	3216-3227	transcripts	_	_	
29-15	3227-3228	,	_	_	
29-16	3229-3234	which	_	_	
29-17	3235-3238	are	_	_	
29-18	3239-3248	expressed	_	_	
29-19	3249-3251	at	_	_	
29-20	3252-3253	a	_	_	
29-21	3254-3257	few	_	_	
29-22	3258-3264	copies	_	_	
29-23	3265-3268	per	_	_	
29-24	3269-3273	cell	_	_	
29-25	3273-3274	,	_	_	
29-26	3275-3278	and	_	_	
29-27	3279-3281	to	_	_	
29-28	3282-3294	reproducibly	_	_	
29-29	3295-3301	detect	_	_	
29-30	3302-3304	at	_	_	
29-31	3305-3310	least	_	_	
29-32	3311-3324	approximately	_	_	
29-33	3325-3333	two-fold	_	_	
29-34	3334-3345	differences	_	_	
29-35	3346-3348	in	_	_	
29-36	3349-3352	the	_	_	
29-37	3353-3363	expression	_	_	
29-38	3364-3370	levels	_	_	
29-39	3371-3372	(	_	_	
29-40	3372-3378	Schena	_	_	
29-41	3379-3381	et	_	_	
29-42	3382-3384	al	_	_	
29-43	3384-3385	.	_	_	
29-44	3385-3386	,	_	_	
29-45	3387-3391	Proc	_	_	
29-46	3391-3392	.	_	_	

#Text=Natl.
30-1	3393-3397	Natl	_	_	
30-2	3397-3398	.	_	_	

#Text=Acad.
31-1	3399-3403	Acad	_	_	
31-2	3403-3404	.	_	_	

#Text=Sci.
32-1	3405-3408	Sci	_	_	
32-2	3408-3409	.	_	_	

#Text=USA 93(2):106-149 (1996)).
33-1	3410-3413	USA	_	_	
33-2	3414-3416	93	_	_	
33-3	3416-3417	(	_	_	
33-4	3417-3418	2	_	_	
33-5	3418-3419	)	_	_	
33-6	3419-3420	:	_	_	
33-7	3420-3423	106	_	_	
33-8	3423-3424	-	_	_	
33-9	3424-3427	149	_	_	
33-10	3428-3429	(	_	_	
33-11	3429-3433	1996	_	_	
33-12	3433-3434	)	_	_	
33-13	3434-3435	)	_	_	
33-14	3435-3436	.	_	_	

#Text=Microarray analysis can be performed by commercially available equipment, following manufacturer's protocols, such as by using the Affymetrix GenChip technology, or Incyte's microarray technology.
#Text=[0123] The development of microarray methods for large-scale analysis of gene expression makes it possible to search systematically for molecular markers of cancer classification and outcome prediction in a variety of tumor types.
34-1	3437-3447	Microarray	_	_	
34-2	3448-3456	analysis	_	_	
34-3	3457-3460	can	_	_	
34-4	3461-3463	be	_	_	
34-5	3464-3473	performed	_	_	
34-6	3474-3476	by	_	_	
34-7	3477-3489	commercially	_	_	
34-8	3490-3499	available	_	_	
34-9	3500-3509	equipment	_	_	
34-10	3509-3510	,	_	_	
34-11	3511-3520	following	_	_	
34-12	3521-3535	manufacturer's	_	_	
34-13	3536-3545	protocols	_	_	
34-14	3545-3546	,	_	_	
34-15	3547-3551	such	_	_	
34-16	3552-3554	as	_	_	
34-17	3555-3557	by	_	_	
34-18	3558-3563	using	_	_	
34-19	3564-3567	the	_	_	
34-20	3568-3578	Affymetrix	_	_	
34-21	3579-3586	GenChip	_	_	
34-22	3587-3597	technology	_	_	
34-23	3597-3598	,	_	_	
34-24	3599-3601	or	_	_	
34-25	3602-3610	Incyte's	_	_	
34-26	3611-3621	microarray	_	_	
34-27	3622-3632	technology	_	_	
34-28	3632-3633	.	_	_	
34-29	3634-3635	[	_	_	
34-30	3635-3639	0123	_	_	
34-31	3639-3640	]	_	_	
34-32	3641-3644	The	_	_	
34-33	3645-3656	development	_	_	
34-34	3657-3659	of	_	_	
34-35	3660-3670	microarray	_	_	
34-36	3671-3678	methods	_	_	
34-37	3679-3682	for	_	_	
34-38	3683-3694	large-scale	_	_	
34-39	3695-3703	analysis	_	_	
34-40	3704-3706	of	_	_	
34-41	3707-3711	gene	_	_	
34-42	3712-3722	expression	_	_	
34-43	3723-3728	makes	_	_	
34-44	3729-3731	it	_	_	
34-45	3732-3740	possible	_	_	
34-46	3741-3743	to	_	_	
34-47	3744-3750	search	_	_	
34-48	3751-3765	systematically	_	_	
34-49	3766-3769	for	_	_	
34-50	3770-3779	molecular	_	_	
34-51	3780-3787	markers	_	_	
34-52	3788-3790	of	_	_	
34-53	3791-3797	cancer	_	_	
34-54	3798-3812	classification	_	_	
34-55	3813-3816	and	_	_	
34-56	3817-3824	outcome	_	_	
34-57	3825-3835	prediction	_	_	
34-58	3836-3838	in	_	_	
34-59	3839-3840	a	_	_	
34-60	3841-3848	variety	_	_	
34-61	3849-3851	of	_	_	
34-62	3852-3857	tumor	_	_	
34-63	3858-3863	types	_	_	
34-64	3863-3864	.	_	_	
